The management of HER2-positive (HER2+) breast cancer is undergoing a profound paradigm shift. Once considered an aggressive and challenging subtype, it has become a model for precision oncology. Clinicians are rapidly moving away from historical "one-size-fits-all" maximum-tolerated treatments toward nuanced escalation and de-escalation strategies driven by trial data, novel biomarkers, and highly active next-generation therapeutics.
The clinical insights detailed below are compiled from the practice-changing presentations delivered at last year’s Perspectives in Breast Cancer Care conference. While these highlights represent the current benchmarks of evidence-based medicine, the therapeutic landscape continues to evolve at an unprecedented pace. To stay ahead of these rapid shifts and participate in live, multidisciplinary debates with leading oncology experts, make sure to secure your spot for this year's Perspectives in Breast Cancer Care conference, returning to Washington, D.C. on September 18–19, 2026.
Neoadjuvant and Early-Stage Strategy
Dr. Anna Garrido-Castro led the discussion on optimizing treatment for early stage HER2- positive breast cancer. A major takeaway was the potential to de-escalate treatment for certain patients by excluding carboplatin. The neoCARHP trial showed that a taxane-based regimen without carboplatin (THP) was non-inferior to the platinum-containing regimen (TCbHP) for pathologic complete response (pCR) and caused significantly less toxicity. Similarly, data from HELEN-006 demonstrated that replacing docetaxel and carboplatin with single-agent nab-paclitaxel plus dual HER2 blockade increased pCR rates versus TCbHP, along with a more favorable toxicity profile.
Breakthrough in Metastatic Care
In the metastatic setting, the therapeutic hierarchy is being rewritten by the unprecedented efficacy of antibody-drug conjugates (ADCs). Dr. Ana Sandoval-Leon noted that while first-line therapy has long been a taxane plus trastuzumab and pertuzumab, recent data from DESTINY-Breast09suggests that trastuzumab deruxtecan (T-DXd) plus pertuzumab may be a highly effective first-line regimen. Currently, in the second-line setting, T-DXd remains a preferred choice due to superior progression-free survival (PFS) and overall survival (OS) compared to T-DM1 in the DESTINY-Breast03 trial.
For patients with HR+/HER2+ co-expression, the PATINA trial showed that adding the CDK4/6 inhibitor palbociclib to maintenance endocrine and HER2-targeted therapy significantly improved PFS, establishing it as a recommended maintenance option.
The Precision Revolution: Biomarkers
A central theme of the conference was moving beyond clinical factors like tumor size to molecularly-driven decisions. Dr. Paolo Tarantino discussed the HER2DX genomic assay, which provides a risk score for long-term recurrence and predicts the likelihood of achieving pCR. This 27-gene signature can help identify stage I patients who may actually be at high risk despite conventionally favorable clinical features.
As ADCs expand their reach, diagnostic precision is paramount. Dr. Mohammad Khalalhila highlighted that inter-observer concordance among pathologists distinguishing a true HER2 IHC0 from HER2-Low IHC 1+ is notoriously low (~26%).To enable eligibility for novel ADCs, updated guidelines now require pathologists to clearly distinguish between absent membrane staining (HER2-null) and faint membrane staining in ≤10% of cells (HER2-ultralow).
Managing Brain Metastasis
Brain metastases, which affects up to 50% of patients with metastatic HER2-positive disease, was discussed by Dr. Sarah Sammons. She detailed the impressive intracranial efficacy of modern therapies, specifically highlighting trastuzumab deruxtecan (T-DXd) and the “HER2CLIMB” regimen (tucatinib, trastuzumab, and capecitabine). T-DXd has demonstrated a 12-month CNS PFS of 58.9%, while the HER2CLIMB regimen remains a highly active option with a 47% intracranial overall response rate even in heavily pre-treated patients.
An interesting prognostic tool, “brain metastasis velocity” measures the number of new lesions developing over time following initial radiation. A higher velocity often indicates a poorer survival outlook, helping clinicians identify patients who require more aggressive intracranial interventions. Dr. Sammons notes that for highly selected, asymptomatic cases with lesions smaller than 2 cm, a multidisciplinary team might consider the innovative approach of starting CNS-active systemic therapies first to avoid immediate radiation-related side effects.
Next Gen Strategies
Looking ahead, Dr. Heather MacArthur explored the pipeline featuring bispecific antibodies like zanidatamab and alternative targets like patritumab deruxtecan (an anti-HER3 ADC), which is showing promising responses in heavily pre-treated, resistant HER2+ populations.
Summary
Modern HER2+ breast cancer management is rapidly evolving toward a model that balances absolute treatment efficacy against long-term quality of life. Whether sparing a stage II patient the toxicity of carboplatin based on new non-inferiority data or utilizing the HER2DX assay to identify high-risk stage 1 cases, precision medicine has arrived. As highlighted by faculty, “We are now looking beyond tumor size to the molecular landscape.”
Don’t miss out on the next wave of clinical breakthroughs. From the promise of HER2-directed vaccines to the next generation of bispecific ADCs, the algorithms for care are shifting in real-time. Join us at the 2026 Perspectives in Breast Cancer Care conference to discuss these innovations live and stay at the forefront of the field.
References:
1. Gao HF, Ye GL, Lin Y, et al. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. J Clin Oncol. 2026;44(17):1587-1596. doi: 10.1200/JCO-25-02176.
2. Chen XC, Jiao DC, Qiao JH, et al. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2025;26(1):27-36. doi: 10.1016/S1470-2045(24)00581-3.
3. Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026;394(6):551-562. doi: 10.1056/NEJMoa2508668.
4. Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
5. Cortés J, Hurvitz SA, Im SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7.
6. Metzger O, Mandrekar S, Goel S, et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. N Engl J Med. 2026;394(5):451-462.
7. Tarantino P, Tayob N, Villacampa G, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024;42(31):3652-3665. doi: 10.1200/JCO.23.02170.
8. Tolaney SM, Tung N, Wolff AC, et al. HER2DX genomic test in early-stage HER2-positive breast cancer. ESMO Open. 2024;9(12):103987. doi: 10.1016/j.esmoop.2024.103987.
9. Fernandez AI, Liu M, Bellizzi A, et al. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 2022;8(4):1-4. doi: 10.1001/jamaoncol.2021.7239.
10. Rakha EA, Tan PH, Van Bockstal MR, et al. International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories. Mod Pathol. 2026;39(1):100925. doi: 10.1016/j.modpat.2025.100925.
11. Harbeck N, Ciruelos E, Jerusalem G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7.
12. Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2023;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610.
13. Ramakrishna N, Anders CK, Temin S. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A. JCO Oncol Pract. 2022;18(11):756-758. doi: 10.1200/OP.22.00364.
14. Wang X, Lee KS, Zeng X, et al. Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study. ESMO Open. 2025;10(11):105852. doi: 10.1016/j.esmoop.2025.105852.
15. Krop IE, Masuda N, Mukohara T, et al. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. J Clin Oncol. 2023;41(36):5550-5560. doi: 10.1200/JCO.23.00882.